SCHEMBL4840708

SCHEMBL4840708

CC(Nc1nccc(N(C(=O)Nc2cccc(F)c2)c2ccc(F)cc2)n1)C(C)(C)O

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 16/20 0.72
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
POLB P06746 1/20 0.45
KMT2A Q03164 1/20 0.45
MAPK13 O15264 2/20 0.40
MAPK12 P53778 2/20 0.40
MAPK11 Q15759 2/20 0.40
KIT P10721 1/20 0.38
PDGFRA P16234 1/20 0.38
KDR P35968 1/20 0.38
TP53 P04637 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4840721 1.00 MAPK14 (0.72) MAPK14NPC1RAB9ASMN1; SMN2POLB
SCHEMBL4838892 0.94 MAPK14 (0.67) MAPK14NPC1RAB9ASMN1; SMN2POLB
SCHEMBL4838900 0.94 MAPK14 (0.67) MAPK14NPC1RAB9ASMN1; SMN2POLB
SCHEMBL4835627 0.93 MAPK14 (0.72) MAPK14NPC1RAB9ASMN1; SMN2POLB
SCHEMBL4835636 0.93 MAPK14 (0.72) MAPK14NPC1RAB9ASMN1; SMN2POLB
SCHEMBL4840147 0.92 MAPK14 (0.70) MAPK14NPC1RAB9ASMN1; SMN2POLB
SCHEMBL4840138 0.92 MAPK14 (0.70) MAPK14NPC1RAB9ASMN1; SMN2POLB
SCHEMBL4836040 0.92 MAPK14 (0.73) MAPK14NPC1RAB9ASMN1; SMN2POLB
SCHEMBL4836030 0.92 MAPK14 (0.73) MAPK14NPC1RAB9ASMN1; SMN2POLB
SCHEMBL4839139 0.91 MAPK14 (0.76) MAPK14MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7402589-B2 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2008-07-22 US claimed
US-20050245555-A1 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2005-11-03 US claimed
US-7402589-B2 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2008-07-22 US disclosed
EP-1737830-A1 TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS The Procter and Gamble Company (US) 2007-01-03 EP disclosed
WO-2005105757-A1 TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2005-11-10 WO disclosed
US-20050245555-A1 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245555-A1 Tri-substituted ureas as cytokine inhibitors IL1B, IL1A, IL6 MAPK14 2674/4885NPC1 3402/4885RAB9A 2976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.